FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Qiagen N.V. Stock AnalysisComprehensive stock analysis for Qiagen N.V. (QGEN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisQGEN
QGEN
Qiagen N.V.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
QGEN
Home🔹Stocks🔹Qiagen N.V.

Qiagen N.V.

🇺🇸QGEN•NYSE

Qiagen N.V.

🇺🇸QGEN•NYSE
Market cap
$8.77B
Sentiment

Your view on QGEN

Mkt Cap
$8.77B
Sentiment
Your view
QGEN
Qiagen N.V.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
QGEN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Qiagen N.V.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Thierry Bernard
Headquarters
Hulsterweg 82, Venlo, NL
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Thierry Bernard
Headquarters
Hulsterweg 82, Venlo, NL
Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.

Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.

It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Qiagen N.V., and the rating behind it. QGEN last traded at $42.50, 21.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Qiagen N.V.. Starting points for Qiagen N.V.: P/E 21.7, EPS $1.98, beta 0.63 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Qiagen N.V.. Qiagen N.V. paid $2.64 per share over the last year — a 6.2% yield at the current $42.50 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Qiagen N.V.. Trailing twelve-month EPS for Qiagen N.V. stands at $1.98. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Qiagen N.V.. Qiagen N.V. has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Qiagen N.V. valued side by side against its closest peers. Qiagen N.V. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Qiagen N.V., and how their positions are changing. At a $8.77B market value, institutional positions materially move Qiagen N.V.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Qiagen N.V. executives and directors. Shares of Qiagen N.V. have traded between $37.63 and $51.88 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Qiagen N.V.. Qiagen N.V. is a $8.77B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Qiagen N.V.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Qiagen N.V.. Coverage tracks Qiagen N.V. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ALGN — Align Technology, Inc.
  • BAX — Baxter International Inc.
  • BMRN — BioMarin Pharmaceutical Inc.
  • CRL — Charles River Laboratories International, Inc.
  • ENSG — The Ensign Group, Inc.
  • EXEL — Exelixis, Inc.
  • HIMS — Hims & Hers Health, Inc.
  • ICLR — ICON Public Limited Company

More Medical - Diagnostics & Research companies

  • GRAL — GRAIL, Inc.
  • GSS.AX — Genetic Signatures Limited
  • HLS.AX — Healius Limited
  • HTGMQ — HTG Molecular Diagnostics, Inc.
  • IBX.AX — Imagion Biosystems Limited
  • IBXXF — Imagion Biosystems Limited
  • ICBU — iMD Companies, Inc.
  • IDGXF — Integrated Diagnostics Holdings plc
  • IDX.AX — Integral Diagnostics Limited
  • IDXG — Interpace Biosciences, Inc.
  • IDXX — IDEXX Laboratories, Inc.

ETFs holding Qiagen N.V.

  • GNOM — Global X - Genomics & Biotechnology ETF (3.26%)
  • EKG — First Trust Nasdaq Lux Digital Health Solutions ETF (2.86%)
  • PBE — Invesco Biotechnology & Genome ETF (2.79%)
  • FXH — First Trust Health Care AlphaDEX Fund (1.79%)
  • FHH.TO — First Trust AlphaDEX U.S. Health Care Sector Index ETF (1.79%)
  • GPT — Intelligent Alpha Atlas ETF (1.63%)
  • HTEC — ROBO Global Healthcare Technology and Innovation ETF (1.52%)
  • BBH — VanEck Biotech ETF (1.02%)

News

Latest Market News